Tiziana Life Sciences has pointed to increased Big Pharma interest in the IL-6 pathway as justification for its ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that it intends to develop its ...

The IL-6 receptor antagonist market presents significant opportunities in underexplored areas like thyroid eye disease and atherosclerotic cardiovascular disease (ASCVD). Recent acquisitions and ...

Wilforine（ 雷公藤 次碱，AbMole，M6228）在免疫调节研究中最显著的特征是其对适应性免疫反应的广泛抑制作用。实验研究表明，Wilforine（雷公藤次碱，CAS No.：11088-09-8）在以溶血素反应为指标的 体液免疫 测定中表现出明显的抑制活性。在动物模型中，Wilforine以40 mg/kg的剂量腹腔注射，可显著降低小鼠的溶血素水平 [1]，表明其对B淋巴细胞介导的抗 ...

Type 1 diabetes (T1D) is an autoimmune disorder characterized by the specific destruction of insulin-producing pancreatic β-cells.

Tiziana Life Sciences considers the antibody, known as TZLS-501, to have potential to operate as a standalone business and intends to proceed with steps for a publicly-listed immunology-focused ...

New research uncovers the exact immune-to-brain pathway that drives the loss of social motivation during sickness.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday it plans to spin out its anti-IL-6 receptor antibody program, TZLS-501, into a separately ...

Soficitinib is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders. The Current indications under development are ...

Ischemic stroke is a complex cerebrovascular disorder characterized by highly unpredictable outcomes influenced by ...